Comparative Pharmacology
Head-to-head clinical analysis: CORVERT versus MULTAQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORVERT versus MULTAQ.
CORVERT vs MULTAQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibutilide, a class III antiarrhythmic agent, prolongs atrial and ventricular refractoriness by blocking delayed rectifier potassium current (IKr) and activating slow inward sodium current (INa-S).
Dronedarone is a multichannel blocker that inhibits potassium currents (IKr, IKs, IK-ACh), sodium current (INa), and L-type calcium current (ICaL), and has antiadrenergic properties via noncompetitive blockade of beta-adrenergic receptors.
1 mg intravenously over 10 minutes; repeat once after 10 minutes if conversion to sinus rhythm not achieved. Maximum total dose: 2 mg.
400 mg orally twice daily with morning and evening meals.
None Documented
None Documented
Terminal elimination half-life is approximately 6 hours (range 2–12 hours) in patients with normal renal function. Prolonged in renal impairment (up to 16 hours in severe impairment).
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) after oral administration, allowing for twice-daily dosing.
Renal (approximately 82% of total clearance), with about 18% biliary/fecal elimination. Mostly unchanged drug and metabolites.
Primarily fecal (84%) after biliary excretion; renal excretion accounts for <6% as unchanged drug and metabolites.
Category C
Category C
Antiarrhythmic
Antiarrhythmic